The rise and fall of β-agonists in the treatment of ARDS

Critical Care

Volumn 16, Issue 2, 2012, Pages

  Bassford, Christopher R ^a   Thickett, David R ^b   Perkins, Gavin D ^c  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; IPRATROPIUM BROMIDE; ORCIPRENALINE; SALBUTAMOL; TERBUTALINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; BRONCHODILATATION; CLINICAL TRIAL; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LACTIC ACIDOSIS; LOW DRUG DOSE; LUNG ALVEOLUS EPITHELIUM; LUNG ENDOTHELIUM; LUNG FLUID; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE RELAXATION; TACHYCARDIA; VASODILATATION; ANIMAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

ADRENERGIC BETA-AGONISTS; ANIMALS; HUMANS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84858750300     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11221     Document Type: Review

References (41)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000, 342:1334-1349. 10.1056/NEJM200005043421806, 10793167.
2. Adhikari N, Burns KE, Meade MO. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2004, CD004477.
3. The Acute Respiratory Distress Syndrome Network Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000, 342:1301-1308. The Acute Respiratory Distress Syndrome Network.
4. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006, 354:2564-2575.
5. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 2008, 133:1120-1127. 10.1378/chest.07-2134, 18263687.
6. Perkins GD, McAuley DF, Richter A, Thickett DR, Gao F. Bench-to-bedside review: beta2-Agonists and the acute respiratory distress syndrome. Crit Care 2004, 8:25-32. 10.1186/cc2417, 420065, 14975042.
7. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006, 117:18-24. 10.1016/j.jaci.2005.11.012, 16387578.
8. Mutlu GM, Factor P. Alveolar epithelial beta2-adrenergic receptors. Am J Respir Cell Mol Biol 2008, 38:127-134. 2214676, 17709598.
9. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 163:1376-1383.
10. Berthiaume Y, Matthay MA. Alveolar edema fluid clearance and acute lung injury. Respir Physiol Neurobiol 2007, 159:350-359. 10.1016/j.resp.2007.05.010, 2682357, 17604701.
11. Sakuma T, Folkesson HG, Suzuki S, Okaniwa G, Fujimura S, Matthay MA. Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am J Respir Crit Care Med 1997, 155:506-512.
12. Dumasius V, Sznajder JI, Azzam ZS, et al. β2-Adrenergic receptor overexpression increases alveolar fluid clearance and responsiveness to endogenous catecholamines in rats. Circ Res 2001, 89:907-914. 10.1161/hh2201.100204, 11701618.
13. Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med 2011, 17:293-307. 3060975, 21046059.
14. Perkins GD, Nathani N, McAuley DF, Gao F, Thickett DR. In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury. Thorax 2007, 62:36-42. 10.1136/thx.2006.059410, 2111273, 16928710.
15. Bloemen PG, van den Tweel MC, Henricks PA, et al. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 1997, 272:L580-L587.
16. Maris NA, de Vos AF, Dessing MC, et al. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005, 172:878-884. 10.1164/rccm.200503-451OC, 15994467.
17. Farmer P, Pugin J. beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 2000, 279:L675-L682.
18. Tan KS, Nackley AG, Satterfield K, Maixner W, Diatchenko L, Flood PM. Beta2 adrenergic receptor activation stimulates pro-inflammatory cytokine production in macrophages via PKA- and NF-kappaB-independent mechanisms. Cell Signal 2007, 19:251-260. 10.1016/j.cellsig.2006.06.007, 16996249.
19. Minnear FL, DeMichele MA, Moon DG, Rieder CL, Fenton JW. Isoproterenol reduces thrombin-induced pulmonary endothelial permeability in vitro. Am J Physiol 1989, 257:H1613-H1623.
20. Takashima S, Schlidt SA, Koukoulis G, Sevala M, Egan TM. Isoproterenol reduces ischemia-reperfusion lung injury despite beta-blockade. J Surg Res 2005, 126:114-120. 10.1016/j.jss.2005.01.017, 15916984.
21. Perkins GD, Gao F, Thickett DR. In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax 2008, 63:215-220. 10.1136/thx.2007.080382, 17951278.
22. Basran GS, Hardy JG, Woo SP, Ramasubramanian R, Byrne AJ. Beta-2-adrenoceptor agonists as inhibitors of lung vascular permeability to radiolabelled transferrin in the adult respiratory distress syndrome in man. Eur J Nucl Med 1986, 12:381-384.
23. Pesenti A, Pelosi P, Rossi N, Aprigliano M, Brazzi L, Fumagalli R. Respiratory mechanics and bronchodilator responsiveness in patients with the adult respiratory distress syndrome. Crit Care Med 1993, 21:78-83. 10.1097/00003246-199301000-00016, 8420734.
24. Wright PE, Carmichael LC, Bernard GR. Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest 1994, 106:1517-1523. 10.1378/chest.106.5.1517, 7956413.
25. Morina P, Herrera M, Venegas J, Mora D, Rodriguez M, Pino E. Effects of nebulized salbutamol on respiratory mechanics in adult respiratory distress syndrome. Intensive Care Med 1997, 23:58-64. 10.1007/s001340050291, 9037641.
26. Manocha S, Gordon AC, Salehifar E, Groshaus H, Walley KR, Russell JA. Inhaled beta-2 agonist salbutamol and acute lung injury: an association with improvement in acute lung injury. Crit Care 2006, 10:R12. 10.1186/cc3971, 1550825, 16420663.
27. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006, 173:281-287. 10.1164/rccm.200508-1302OC, 16254268.
28. Licker M, Tschopp JM, Robert J, Frey JG, Diaper J, Ellenberger C. Aerosolized salbutamol accelerates the resolution of pulmonary edema after lung resection. Chest 2008, 133:845-852. 10.1378/chest.07-1710, 17989152.
29. Craig TR, Duff y MJ, Shyamsundar M, et al. Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injury. Crit Care Med 2010, 38:114-120. 10.1097/CCM.0b013e3181b43050, 19789451.
30. Effros RM. The beta-agonist lung injury trial (BALTI). Am J Respir Crit Care Med 2006, 173:1290.
31. Matthay MA, Brower RG, Carson S, et al. Randomized, placebo-controlled clinical trial of an aerosolized beta-2 agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011, 184:561-568.
32. Perkins GD, Gates S, Lamb SE, McCabe C, Young D, Gao F. Beta Agonist Lung Injury Trial-2 (BALTI-2) trial protocol: a randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome. Trials 2011, 12:113. 10.1186/1745-6215-12-113, 3113985, 21554679.
33. Smith FG, Perkins GD, Gates S, et al. The effect of intravenous beta-2 agonist therapy on clinical outcomes in the acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet
34. Perkins GD, Park D, Alderson D, et al. The Beta Agonist Lung Injury Trial (BALTI)-prevention trial protocol. Trials 2011, 12:79. 10.1186/1745-6215-12-79, 3068101, 21406094.
35. Newhouse MT, Chapman KR, McCallum AL, et al. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest 1996, 110:595-603. 10.1378/chest.110.3.595, 8797398.
36. Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 2002, 121:846-851. 10.1378/chest.121.3.846, 11888971.
37. Briot R, Bayat S, Anglade D, Martiel JL, Grimbert F. Increased cardiac index due to terbutaline treatment aggravates capillary-alveolar macromolecular leakage in oleic acid lung injury in dogs. Crit Care 2009, 13:R166. 10.1186/cc8137, 2784397, 19845949.
38. Abel SJ, Finney SJ, Brett SJ, Keogh BF, Morgan CJ, Evans TW. Reduced mortality in association with the acute respiratory distress syndrome (ARDS). Thorax 1998, 53:292-294. 10.1136/thx.53.4.292, 1745195, 9741374.
39. Stratakos G, Kalomenidis J, Routsi C, Papiris S, Roussos C. Transient lactic acidosis as a side effect of inhaled salbutamol. Chest 2002, 122:385-386. 10.1378/chest.122.1.385, 12114394.
40. Day NP, Phu NH, Bethell DP, et al. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 1996, 348:219-223. 10.1016/S0140-6736(96)09096-4, 8684198.
41. Atabai K, Ware LB, Snider ME, et al. Aerosolized beta(2)-adrenergic agonists achieve therapeutic levels in the pulmonary edema fluid of ventilated patients with acute respiratory failure. Intensive Care Med 2002, 28:705-711. 10.1007/s00134-002-1282-x, 12107675.